Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Design Validation of Senofilcon A With New UV-blocking Additive
NCT03707821 · View on ClinicalTrials.gov ↗
Study Summary
This is a 2-visit, multi-site, partially subject-masked, 2-arm parallel, controlled, randomized and dispensing trial. Subjects will be randomized to one of two study lenses for the entire duration of the study. The study lenses will be worn for a period of 2 weeks each in a bilateral fashion.
Conditions Studied
Interventions
- DEVICE senofilcon A TEST Lens
- DEVICE senofilcon A CONTROL Lens
Study Locations (10)
Florida
- Maitland Vision Center — Maitland
- Tallahassee Eye Center — Tallahassee
Ohio
- ProCare Vision Centers — Granville
- Professional Vision Care, Inc — Westerville
California
- James T. Fujimoto, OD — Cupertino
Illinois
- Eyecare Associates LLP — Bloomington
Kansas
- Kannarr Eye Care — Pittsburg
Tennessee
- Bradley Hines, OD — Memphis
Texas
- Frazier Vision, Inc — Tyler
Wisconsin
- Ziegler Leffingwell Eyecare — New Berlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 253 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2018-11-01 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03707821
The ClinicalTrials.gov registry entry for NCT03707821 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 253 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Vision Care, which has 36 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Visual Acuity appearing as the primary indexed condition, and to 2 interventions — of which senofilcon A TEST Lens is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03707821 reports 10 study locations spanning 8 distinct geographic areas — top geographies include Florida, Ohio, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03707821 about?
NCT03707821 is a clinical study titled "Design Validation of Senofilcon A With New UV-blocking Additive". This is a 2-visit, multi-site, partially subject-masked, 2-arm parallel, controlled, randomized and dispensing trial. Subjects will be randomized to one of two study lenses for the entire duration of the study. The study lenses will be worn for a period of 2 weeks each in a bilateral fashion.
What is the current status of trial NCT03707821?
This trial is currently completed. It is a NA study. The enrollment target is 253 participants. The study started on 2018-10-01. Estimated completion is 2018-11-01.
What conditions does trial NCT03707821 study?
This clinical trial studies the following conditions: Visual Acuity. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03707821?
The interventions under investigation include: senofilcon A TEST Lens (DEVICE), senofilcon A CONTROL Lens (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03707821?
This trial is sponsored by Johnson & Johnson Vision Care, which has 36 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03707821 being conducted?
This trial has 10 study locations across California, Florida, Illinois, Kansas, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.